Gabriela Hobbs/Massachusetts General Hospital
Sep 4, 2025, 18:00
SOHO 2025: Gabriela Hobbs on Emerging Strategies for Managing Polycythemia Vera and Essential Thrombocythemia
MPN Hub shared on X:
”CONGRESS | SOHO 2025 | PRESENTATION
Gabriela Hobbs, Massachusetts General Hospital News
Discusses novel therapies in development for treatment of Polycythemia Vera, including modulators of hepcidin-ferroportin, bomedemstat, givinostat, and novel JAKis, and in Essential Thrombocythemia, including ropeginterferon, bomedemstat, and CALR-directed agents.
Follow our live feed for more updates.”
Find more slides in the gallery.
All on Hemostasis and Thrombosis from SOHO 2025 featured in Hemostasis Today.
-
Feb 16, 2026, 15:44Lakmali Silva: Silva Lab Showcases Research at the Gordon Research Conference on Plasminogen and Extracellular Proteolysis
-
Feb 16, 2026, 15:36Heghine Khachatryan: Strengthening Maternal Resilience Against Postpartum Hemorrhage
-
Feb 16, 2026, 15:34Sevak Mirabyan: Advancing Cancer Care Through Knowledge, Collaboration, and Early Diagnosis in Armenia
-
Feb 16, 2026, 15:29Chokri Ben Lamine: Key Clinical Insights of Drug Induced Thrombocytopenia
-
Feb 16, 2026, 15:28Ney Carter Borges: Coronary Intravascular Lithotripsy – Clinical Performance and Safety
-
Feb 16, 2026, 15:24Flora Peyvandi: Highlighting Overdose, Homicide, and Suicide as Causes of Maternal Death in the US
-
Feb 16, 2026, 14:53Wafaa Abougabal: Differential Diagnosis of Acute Neurologic Deficits and Stroke in PICU
-
Feb 16, 2026, 14:49Nayab Ahmed: Synthesis of ATP and Its Significance in Storage of Blood
-
Feb 16, 2026, 14:44Lukasz Kuzma: NOAC Monotherapy vs NOAC Plus Clopidogrel in AF Beyond One Year After DES